Immunoglobulin E (anti-IgE, omalizumab), interleukin 5 (anti-IL5, mepolizumab and reslizumab) and its receptor alpha (anti-IL5Rα, benralizumab), interleukin 4 receptor alpha (anti-IL4Rα, dupilumab), and, more recently, thymic stromal lymphopoietin (anti-TSLP, tezepeluma [4], have shown promise in reducing exacerbations and hospitalizations, improving lung function, asthma control and quality of life, and limiting the use of systemic corticosteroids, with a favorable safety profile [3]. Here, IL5 is linked to asthma.